Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Clinical Trial Sponsors Struggle with Data Disclosure Requirements

November 25, 2013

Research sponsors argue that widening access to patient level data from clinical trials will undermine patient privacy and incentives for new drug development.

Pharm Exec Roundtable on Market Access

November 25, 2013

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible—hope.

What Does the UK's 'New' PPRS Mean for Value-Based Pricing?

November 20, 2013

Leela Barham ponders the future of VBP in the light of a new PPRS deal between industry and the UK government.

Clearing the Emerging Market Hurdles

November 18, 2013

Despite the long-held promise of the emerging markets, dominance in these territories has eluded Big Pharma. Hussain Mooraj addresses the key issues and offers a strategy for success.

Get Real: Preparing for the Real World Evidence Future

November 12, 2013

Why Real World Evidence (RWE) is here to stay, and what you need to do to integrate it into your business strategy as painlessly as possible.

Brazil Improves Access to Experimental Drugs

November 11, 2013

New regulation offers drug options for patients with rare, severe, or debilitating illnesses.

Defying Gravity at the Patent Cliff

November 2, 2013

Pharmaceutical companies are using formulation strategies as a lifecycle management tool to maximize product value and preserve their revenue streams.

2014 Pipeline Report: The Sprint to Value

November 1, 2013

Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.

Supply Chain: Scanning the Future

November 1, 2013

The US and Europe are moving toward the enactment of new legislation that will change the way pharma products are handled and shipped throughout the supply chain.

ADVERTISEMENT

Click here